Skip to main content
. 2012 Apr;22(4):369–376. doi: 10.1089/thy.2011.0198

FIG. 2.

FIG. 2.

Distribution of four outcome stages in the study groups, at the end of follow-up. S0 indicates no clinical evidence of disease and either stimulated or suppressed Tg<1.0 ng/mL; S1 indicates no clinical evidence of disease with detectable Tg (≥1.0 ng/mL); S2 indicates clinically detectable disease; S3 indicates death from thyroid cancer. Ab+ indicates patients with no clinical evidence of residual disease, but with persistent positive Tg antibody.